The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | COVID-19 in patients with hematologic malignancies
Lindsay Wilde, MD, Thomas Jefferson University, Philadelphia, PA shares the findings of an investigation into the clinical impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on patients with hematologic malignancies, including multiple myeloma, diffuse large B-cell lymphoma, and mantle cell lymphoma. Of the small cohort of 21 patients who contracted COVID-19, 20 required hospitalization, 7 were admitted to the ICU, 6 required intubation, and 3 patients died. The patients that died were above the age of 70 and were former smokers. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
